@Amanda_Bok @jangeissler @EHA_Hematology @EHC_Haemophilia Spot on! Patients’ attitudes about benefit-risk do change over time with disease progression, and so do naturally the outcomes that matter most. Do you remember the findings from the 2016 study with
How do you #quantify the #longterm #risksvbeneftis of #medicine Oxidative phosphorylation #oxidativestress https://t.co/X6m7cOdV0J
Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers https://t.co/HkQnLyKRbA #ojrd
Not surprising pts/caregivers willing to accept more risk|Quantifying benefit-risk for #raredisease drugs https://t.co/fx4o04qu3A #hcmktg